Cargando…

Ivabradine: A Potential Therapeutic for Children With Refractory SVT

Background: In April 2015, ivabradine was approved by the Food and Drug Administration for the treatment of patients with coronary artery disease and heart failure (HF). The use of this medication has been linked with improved clinical outcomes and reduced rates of hospitalization in patients with s...

Descripción completa

Detalles Bibliográficos
Autores principales: Younis, Nour K., Abi-Saleh, Bernard, Al Amin, Farah, El Sedawi, Omar, Tayeh, Christelle, Bitar, Fadi, Arabi, Mariam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8368123/
https://www.ncbi.nlm.nih.gov/pubmed/34414216
http://dx.doi.org/10.3389/fcvm.2021.660855
_version_ 1783739151528493056
author Younis, Nour K.
Abi-Saleh, Bernard
Al Amin, Farah
El Sedawi, Omar
Tayeh, Christelle
Bitar, Fadi
Arabi, Mariam
author_facet Younis, Nour K.
Abi-Saleh, Bernard
Al Amin, Farah
El Sedawi, Omar
Tayeh, Christelle
Bitar, Fadi
Arabi, Mariam
author_sort Younis, Nour K.
collection PubMed
description Background: In April 2015, ivabradine was approved by the Food and Drug Administration for the treatment of patients with coronary artery disease and heart failure (HF). The use of this medication has been linked with improved clinical outcomes and reduced rates of hospitalization in patients with symptomatic HF and a baseline heart rate of 70 bpm and above. Nonetheless, little is known about the use of ivabradine in pediatric patients with supraventricular tachycardia (SVT). This use is not well-studied and is only endorsed by a few case reports and case series. Aim: This study discusses the off-label utilization of ivabradine in pediatric patients with SVT, and highlights its efficacy in treating treatment-resistant (refractory) SVT. Methods: We conducted a retrospective single-center observational study involving pediatric patients with SVT treated at our center between January 2016 and October 2020. We identified the total number of patients with SVT, and the number of patients with refractory SVT treated with Ivabradine. Similarly, we performed a thorough review of the databases of PubMed, Medline and Google Scholar to compare the clinical course of our patients to those described in the literature. Results: Between January 2016 and October 2020, 79 pediatric patients with SVT were seen and treated at our center. A treatment-resistant SVT was noted only in three patients (4%). Ivabradine was used in these patients as a single or combined therapy. The rest (96%) were successfully treated with conventional anti-arrhythmics such as β-blockers, flecainide, and other approved medications. In the ivabradine group, successful reversal to sinus rhythm was achieved in two of the three patients (66%), one patient was treated with a combination therapy of amiodarone and ivabradine, and the other patient was treated only with ivabradine. Conclusion: Overall, promissory results are associated with the use of ivabradine in pediatric patients with refractory SVT. Ivabradine appears to be a safe and well-tolerated medication that can induce adequate suppression of SVT, complete reversal to sinus rhythm, and effective enhancement of left ventricular function.
format Online
Article
Text
id pubmed-8368123
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-83681232021-08-18 Ivabradine: A Potential Therapeutic for Children With Refractory SVT Younis, Nour K. Abi-Saleh, Bernard Al Amin, Farah El Sedawi, Omar Tayeh, Christelle Bitar, Fadi Arabi, Mariam Front Cardiovasc Med Cardiovascular Medicine Background: In April 2015, ivabradine was approved by the Food and Drug Administration for the treatment of patients with coronary artery disease and heart failure (HF). The use of this medication has been linked with improved clinical outcomes and reduced rates of hospitalization in patients with symptomatic HF and a baseline heart rate of 70 bpm and above. Nonetheless, little is known about the use of ivabradine in pediatric patients with supraventricular tachycardia (SVT). This use is not well-studied and is only endorsed by a few case reports and case series. Aim: This study discusses the off-label utilization of ivabradine in pediatric patients with SVT, and highlights its efficacy in treating treatment-resistant (refractory) SVT. Methods: We conducted a retrospective single-center observational study involving pediatric patients with SVT treated at our center between January 2016 and October 2020. We identified the total number of patients with SVT, and the number of patients with refractory SVT treated with Ivabradine. Similarly, we performed a thorough review of the databases of PubMed, Medline and Google Scholar to compare the clinical course of our patients to those described in the literature. Results: Between January 2016 and October 2020, 79 pediatric patients with SVT were seen and treated at our center. A treatment-resistant SVT was noted only in three patients (4%). Ivabradine was used in these patients as a single or combined therapy. The rest (96%) were successfully treated with conventional anti-arrhythmics such as β-blockers, flecainide, and other approved medications. In the ivabradine group, successful reversal to sinus rhythm was achieved in two of the three patients (66%), one patient was treated with a combination therapy of amiodarone and ivabradine, and the other patient was treated only with ivabradine. Conclusion: Overall, promissory results are associated with the use of ivabradine in pediatric patients with refractory SVT. Ivabradine appears to be a safe and well-tolerated medication that can induce adequate suppression of SVT, complete reversal to sinus rhythm, and effective enhancement of left ventricular function. Frontiers Media S.A. 2021-08-03 /pmc/articles/PMC8368123/ /pubmed/34414216 http://dx.doi.org/10.3389/fcvm.2021.660855 Text en Copyright © 2021 Younis, Abi-Saleh, Al Amin, El Sedawi, Tayeh, Bitar and Arabi. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cardiovascular Medicine
Younis, Nour K.
Abi-Saleh, Bernard
Al Amin, Farah
El Sedawi, Omar
Tayeh, Christelle
Bitar, Fadi
Arabi, Mariam
Ivabradine: A Potential Therapeutic for Children With Refractory SVT
title Ivabradine: A Potential Therapeutic for Children With Refractory SVT
title_full Ivabradine: A Potential Therapeutic for Children With Refractory SVT
title_fullStr Ivabradine: A Potential Therapeutic for Children With Refractory SVT
title_full_unstemmed Ivabradine: A Potential Therapeutic for Children With Refractory SVT
title_short Ivabradine: A Potential Therapeutic for Children With Refractory SVT
title_sort ivabradine: a potential therapeutic for children with refractory svt
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8368123/
https://www.ncbi.nlm.nih.gov/pubmed/34414216
http://dx.doi.org/10.3389/fcvm.2021.660855
work_keys_str_mv AT younisnourk ivabradineapotentialtherapeuticforchildrenwithrefractorysvt
AT abisalehbernard ivabradineapotentialtherapeuticforchildrenwithrefractorysvt
AT alaminfarah ivabradineapotentialtherapeuticforchildrenwithrefractorysvt
AT elsedawiomar ivabradineapotentialtherapeuticforchildrenwithrefractorysvt
AT tayehchristelle ivabradineapotentialtherapeuticforchildrenwithrefractorysvt
AT bitarfadi ivabradineapotentialtherapeuticforchildrenwithrefractorysvt
AT arabimariam ivabradineapotentialtherapeuticforchildrenwithrefractorysvt